新股首日 | 賽生藥業午後翻紅漲超2%
uSMART盈立智投3月3日消息,上市首日,賽生藥業低開低走,午後由跌轉漲,截至13:52分,賽生藥業盤中漲超2%。
相較諾輝健康-B的逾100萬人申購,賽生藥業的申購人數約43.6萬,公開認購倍數爲1,068.05倍,國配認購倍數10倍,在目前動輒幾十倍的國配數據下,國配認購算不上火爆。
賽生藥業的乙組認購倍數高達1570倍,是甲組(566倍)的近3倍。乙組繼續呈"內卷"趨勢。
賽生藥業的國配貨源集中,合共211名承配人,前25名承配人合共鎖定58.41%的發行股份,其中,上藥國際等11名基石合共鎖定47.53%的發行股份,禁售期6個月。也就是說,流動股份主要掌握在50%的公開散戶手中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.